General Toxicity Notes
Blood pressure is the best guide to dose and interval. Hyperkalemia in ESRD.
Excreted Unchanged %
30-40
Half-Life (Normalesrd) Hours
3-13/7
Plasma Protein Binding %
26
Volume Of Distribution L/Kg
1.2
Dose For Normal Renal Function
400-600 mg q24h or bid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50,titrate, [D]
References
Fleurot O, Lecocq B, Lecocq V, Le Liboux A, Montay G, Frydman A, et al. A comparative pharmacokinetic and pharmacodynamic study of conventional and sustained-release preparations of acebutolol in healthy volunteers. Fundam Clin Pharmacol. 1991; 5: 601-9. [PMID: 1778538] / Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Pharmacokinetics of acebutolol enantiomers in humans. J Pharm Sci. 1991; 80: 313-6. [PMID: 1865329] / Singh BN, Thoden WR, Ward A. Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs. 1985; 29: 531-69. [PMID: 3891306] / Tjandramaga TB. Altered pharmacokinetics of beta-adrenoceptor blocking drugs in patients with renal insufficiency. Arch Int Pharmacodyn Ther. 1980; Suppl: 38-53. [PMID: 6106457]
Toxicity Notes
Active metabolites with long half-life.